Related Experiment Videos
[Pharmacokinetic studies of micronomicin using a continuous intravenous infusion method]
Abstract:
The basic pharmacokinetics of micronomicin (MCR) were studied in 4 healthy adult volunteers. MCR 60 and 120 mg were intravenously administered in 30 and 60 minutes at constant rates by means of continuous infusion apparatus. The same dosages were also tested by intramuscular route. The concentrations of MCR in serum and urine were determined by HPLC and analyzed following the two-compartment open model after intravenous treatment and following the one-compartment open model after intramuscular treatment. When MCR was given by intramuscular route, the mean serum concentration of 4 subjects reached a peak of 3.98 micrograms/ml at 30 minutes after a dose of 60 mg and 6.7 micrograms/ml at 30 minutes after that of 120 mg. The peak concentration was achieved at the end of intravenous infusion and was dose-related, since it was 6.1 and 10.5 micrograms/ml after a 30-minute infusion of 60 and 120 mg, respectively, and 4.85 and 9.43 micrograms/ml after a 60-minute infusion of 60 and 120 mg, respectively. At 8 hours, concentrations dropped to less than 0.1 microgram/ml and to 0.2 microgram/ml or less after 60 and 120 mg, respectively, regardless of the route and rate of administration. The mean urinary recovery up to 8 hours ranged 84 to 92% of the dose. There were no appreciable differences in pharmacokinetic parameters among 4 modes of intravenous infusion, with a T1/2(beta) of 1.43 approximately 2.02 hours. In the case of intramuscular treatment, parameters analyzed following the one-compartment open model were on similar levels to corresponding values found after intravenous treatment and the T1/2 was 1.39 hours after 60 mg and 1.43 hours after 120 mg.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
This study on micronomicin (MCR) pharmacokinetics in healthy adults found similar absorption and elimination profiles for both intravenous and intramuscular routes. Urinary recovery was high, indicating efficient excretion of MCR.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Clinical Pharmacology
- Aminoglycoside Antibiotics
Background:
- Micronomicin (MCR) is an aminoglycoside antibiotic.
- Understanding its pharmacokinetic profile is crucial for safe and effective therapeutic use.
- Limited data exists on MCR's absorption, distribution, metabolism, and excretion (ADME) in humans.
Purpose of the Study:
- To investigate the basic pharmacokinetics of micronomicin (MCR) in healthy adult volunteers.
- To compare MCR's pharmacokinetic parameters following intravenous (IV) and intramuscular (IM) administration.
- To evaluate the influence of different infusion rates on MCR pharmacokinetics.
Main Methods:
- Four healthy adult volunteers received MCR (60 mg and 120 mg) via IV infusion (30 and 60 minutes) and IM injection.
- Serum and urine concentrations of MCR were quantified using High-Performance Liquid Chromatography (HPLC).
- Pharmacokinetic analysis was performed using a two-compartment open model for IV administration and a one-compartment open model for IM administration.
Main Results:
- Peak serum concentrations of MCR were dose-dependent and achieved at the end of IV infusion or 30 minutes post-IM injection.
- Serum concentrations declined rapidly, falling below 0.1-0.2 mcg/ml within 8 hours, irrespective of administration route or IV infusion rate.
- Mean urinary recovery of MCR ranged from 84% to 92% within 8 hours, with similar elimination half-lives (T1/2(beta) approx. 1.4-2.0 hours) for both IV and IM routes.
Conclusions:
- Micronomicin exhibits predictable pharmacokinetics following both intravenous and intramuscular administration in healthy adults.
- The drug is rapidly eliminated, with high urinary recovery suggesting efficient renal excretion.
- Pharmacokinetic parameters are comparable between IV and IM routes, supporting the potential utility of intramuscular administration for MCR.